How a diabetes drug helps heal heart blood vessels after a heart attack

Original Title

SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways

Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms

Summary

A diabetes medicine called dapagliflozin helps protect tiny blood vessels in the heart after they get damaged during a heart attack by fixing calcium leaks and reducing stress in the vessel walls.

Sign up to see full results

Get access to research results, context, and detailed analysis.

Surprising Findings

Dapagliflozin works in human heart blood vessel cells—even though the study was done in mice and lab-grown cells.

Most animal studies don’t translate to human cells, but here, the same molecular pathway (XO-SERCA2-CaMKII-cofilin) was confirmed in both mouse models and human coronary artery endothelial cells (HCAECs), making it far more credible.

Practical Takeaways

If you or a loved one has diabetes and a history of heart issues, ask your doctor if dapagliflozin (Farxiga) might be appropriate—even if your blood sugar is controlled.

medium confidence

Unlock Full Study Analysis

Sign up free to access quality scores, evidence strength analysis, and detailed methodology breakdowns.

8%
Lower QualityOverall Score

Publication

Journal

Theranostics

Year

2022

Authors

Li Ma, Rongjun Zou, Wanting Shi, Na Zhou, Shaoxian Chen, Hao Zhou, Xinxin Chen, Yueheng Wu

Open Access
100 citations
Analysis v1